Analytical Data
-
Gene name
CTNS
- Application
-
Alternative Names
CTNS；Cystinosin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O60931
-
Expression Region
1-367aa
-
AA Sequence
MIRNWLTIFILFPLKLVEKCESSVSLTVPPVVKLENGSSTNVSLTLRPPLNATLVITFEITFRSKNITILELPDEVVVPPGVTNSSFQVTSQNVGQLTVYLHGNHSNQTGPRIRFLVIRSSAISIINQVIGWIYFVAWSISFYPQVIMNWRRKSVIGLSFDFVALNLTGFVAYSVFNIGLLWVPYIKEQFLLKYPNGVNPVNSNDVFFSLHAVVLTLIIIVQCCLYERGGQRVSWPAIGFLVLAWLFAFVTMIVAAVGVTTWLQFLFCFSYIKLAVTLVKYFPQAYMNFYYKSTEGWSIGNVLLDFTGGSFSLLQMFLQSYNNDQWTLIFGDPTKFGLGVFSIVFDVVFFIQHFCLYRKRPGYDQLN
-
Molecular Weight
41.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CTNS (cystine transporter) is crucial for cellular cystine uptake, and its dysfunction is associated with cystine storage disorders, particularly cystinosis. Cystinosis, a genetic condition, leads to the accumulation of cystine within lysosomes, resulting in significant damage to various organs, particularly the kidneys and eyes. The primary challenge in treating cystinosis has been the lack of effective therapies to address the underlying molecular defect. Research on CTNS recombinant protein has gained traction as scientists aim to understand the structure-function relationship of the protein and its role in cystine transport. By producing and characterizing recombinant CTNS, researchers can investigate its transport mechanisms, identify potential inhibitors, and explore avenues for gene therapy or pharmacological interventions. The goal is to develop targeted strategies that can enhance cystine transport in affected tissues, ultimately improving patient outcomes. Continued studies on the recombinant CTNS protein are essential for advancing our understanding of cystine metabolism and developing innovative therapies for cystinosis and related disorders.
